Scholarlink

<p>This work explores how Autocrine Motility Factor Receptor (AMFR)-driven ubiquitination of Family with Sequence Similarity 134 Member B (FAM134B) in hypoxia adaptation and endoplasmic reticulum-selective autophagy (ER-phagy) in osteosarcoma (OS), aiming to develop a stimuli-responsive nanoplatform (S-SNACs@TPZ@Cas-A) for targeted therapy. Transcriptomic analysis identifies the AMFR-FAM134B axis as crucial for OS survival under hypoxic conditions. The nanoplatform, thoroughly characterized via established methods, co-delivers CRISPR-Cas9 RNP and tirapazamine to disrupt AMFR and enhance reactive oxygen species production, inhibiting tumor growth in mouse models. In vitro assays confirm decreased FAM134B ubiquitination and ER-phagy inhibition. In vivo, S-SNACs@TPZ@Cas-A reduces tumor volume, metastasis, and enhances immune response without significant toxicity. Second near-infrared window imaging validates targeted drug delivery. This approach provides a precise strategy to disrupt hypoxia tolerance in OS and potentially other hypoxia-tolerant tumors, offering promise for improved therapeutic outcomes.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

AMFR-mediated ER-phagy regulation and therapeutic targeting in osteosarcoma: a multifunctional nanoplatform strategy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月18日

查看全文
  • Qirui Zhao,
  • Xiaoqing Lu,
  • Tongtong Xu,
  • Zixuan Gao,
  • Linjia Peng,
  • Binyu Zhu,
  • Weicheng Wang,
  • Zhigang Liu,
  • Guangjie Yang,
  • Hui Zhao,
  • Zhiming Song,
  • Qiankun Lou,
  • Jiaming Li,
  • Zhiguang Ren,
  • Zhe Yu,
  • de la Fuente Jesus M,
  • Daxiang Cui

摘要

This work explores how Autocrine Motility Factor Receptor (AMFR)-driven ubiquitination of Family with Sequence Similarity 134 Member B (FAM134B) in hypoxia adaptation and endoplasmic reticulum-selective autophagy (ER-phagy) in osteosarcoma (OS), aiming to develop a stimuli-responsive nanoplatform (S-SNACs@TPZ@Cas-A) for targeted therapy. Transcriptomic analysis identifies the AMFR-FAM134B axis as crucial for OS survival under hypoxic conditions. The nanoplatform, thoroughly characterized via established methods, co-delivers CRISPR-Cas9 RNP and tirapazamine to disrupt AMFR and enhance reactive oxygen species production, inhibiting tumor growth in mouse models. In vitro assays confirm decreased FAM134B ubiquitination and ER-phagy inhibition. In vivo, S-SNACs@TPZ@Cas-A reduces tumor volume, metastasis, and enhances immune response without significant toxicity. Second near-infrared window imaging validates targeted drug delivery. This approach provides a precise strategy to disrupt hypoxia tolerance in OS and potentially other hypoxia-tolerant tumors, offering promise for improved therapeutic outcomes.

Graphical Abstract